# Contents of volume 17


Abel G, see Rutty CJ, et al. 251
Abels J, see Kroes ACM, et al. 114
Adair CG, McElnay JC: Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil 95
Adair CG, Bridges JM, Desai ZR: Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? 99
Adair CG, Bridges JM, Desai ZR: Renal function in the elimination of oral melphalan in patients with multiple myeloma 185
Aggarwal SK, see Batzer MA 209
Akel G, Benard P, Canal P, Soula G: Distribution and tumor penetration properties of a radiosensitizer 2-[$^{14}$C] misonidazole (Ro 07-0582), in mice and rats as studied by whole-body autoradiography 121
Alexopoulos CG, Chalevelakis G, Katsoulis C, Pallikaris G: Adverse effect of *cis*-diamminedichloroplatinum II (CDDP) on porphyrin metabolism in man 165
Alley MC, see Appel PL, et al. 47
Aoki K, see Iwamoto Y, et al. 247
Appel PL, Alley MC, Lieber MM, Shoemaker R, Powis G: Metabolic stability of experimental chemotherapeutic agents in hepatocyte: tumor cell co-cultures 47
Arlin ZA, Berman E, Jhanwar S, Gams R, Schoch I, Dukart G: Treatment of blastic transformation of chronic myelogenous leukemia with mitozantrone 189

Baba T, see Iwamoto Y, et al. 247
Banham SW, see Cunningham D, et al. 85
Barankiewicz J, see Kaplinsky C, et al. 264
Bartels B, see Peest D, et al. 69
Basinger MA, see Jones MM, et al. 38
Batzer MA, Aggarwal SK: An in vitro screening system for the nephrotoxicity of various platinum coordination complexes. A cytochemical study 209
Belch A, see Brox LW, et al. 127
Benard P, see Akel G, et al. 121
Beriel H, see Riondel J, et al. 137
Berman E, see Arlin ZA, et al. 189
Blanco G, see Kallio S, et al. 103
Blanco G, see Kangas L, et al. 109
Block AL, see Seidenfeld J, et al. 16
Bodey GP, see Lu K, et al. 143
Bore P, Lena N, Imbert AM, Favre R, Cano JP, Meyer G, Carcassonne Y: Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine 171
Bosanquet AG: Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics 1
Bradley CA, see Jones MM, et al. 38
Brasch H, see Iven H, et al. 218
Bridges JM, see Adair CG, et al. 99
Bridges JM, see Adair CG, et al. 185
Brox LW, Belch A, Ng A, Pollock E: Loss of viability and induction of DNA damage in human leukemic myeloblasts and lymphocytes by *m*-AMSA 127
Buamah PK, Cornell C, James OFW, Skillen AW, Harris AL: Serial serum AFP heterogeneity changes in patients with hepatocellular carcinoma during chemotherapy 182
Burgess M, see Lu K, et al. 143

Canal P, see Akel G, et al. 121
Cano JP, see Bore P, et al. 171
Carcassonne Y, see Bore P, et al. 171
Carmo-Pereira J, Oliveira Costa F, Henriques E, Carvalho V: A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer 87
Carpenter L, see Lea MA, et al. 231
Carvalho V, see Carmo-Pereira J, et al. 87
Case LD, see Jackson DV Jr, et al. 281
Casson AG, see Ford CHJ, et al. 197
Chalevelakis G, see Alexopoulos CG, et al. 165
Christensen AB, see Groth S, et al. 191
Clark G, see Hersh MR, et al. 277
Coe P, see Lee FYF, et al. 21
Cohen A, see Kaplinsky C, et al. 264
Cole SPC: Rapid chemosensitivity testing of human lung tumor cells using the MTT assay 259
Cooper MR, see Jackson DV Jr, et al. 281
Cornell C, see Buamah PK, et al. 182
Cox D, see Cullen M, et al. 157
Cripps C, see Stewart DJ, et al. 91
Crivellari D, see Frustaci S, et al. 75
Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, Ward M, Richards M, Stableforth D, Macfarlane A, Stirland J, Woodroffe C, Macfarlane J, Fletcher J, Davies D, The Midlands Small Cell Lung Cancer Group: Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial 157
Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M: Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients 80
Cunningham D, see Cummings J, et al. 80
Cunningham D, Banham SW, Soukop M: Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol 85
Cysyk RL, see Klubes P, et al. 236

Dallmann I, see Peest D, et al. 69
Davies D, see Cullen M, et al. 157
de Graaf SSN, de Vries JA, Zijlstra WG: Influence of high-dose methotrexate on the distribution of body fluid volumes in the dog 227
DeGregorio MW, see Holleran WM, et al. 11
Deicher H, see Peest D, et al. 69
Desai ZR, see Adair CG, et al. 99
Desai ZR, see Adair CG, et al. 185
Deshpande N, see Mitchell I, et al. 289
de Vries JA, see de Graaf SSN, et al. 227
Doll DC: Fatal pneumothorax associated with bleomycin-induced pulmonary fibrosis 294
Drobnik J, see Lázničková, et al. 133
Dukart G, see Arlin ZA, et al. 189

Erb N, Erttmann R, Landbeck G: A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol 53
Erttmann R, see Erb N, et al. 53
Estrov Z, see Kaplinsky C, et al. 264

Favre R, see Bore P, et al. 171
Fennelly JJ, see Pomeroy M, et al. 285
Feun LG, see Lu K, et al. 143
Figoli F, see Frustaci S, et al. 75
Fletcher J, see Cullen M, et al. 157
Ford CHJ, Casson AG: Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview 197
Forrest GJ, see Cummings J, et al. 80
Fox BW, see Hartley JA 56
Fox BW, see McGown AT 223
Freedman MH, see Kaplinsky C, et al. 264
Frustaci S, Grattoni E, Tumolo S, Crivellari D, Figoli F, Galligioni E, Veronesi A, Tirelli U, Grigoletto E: Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose IV metoclopramide and high-dose IV dexamethasone 75

Galligioni E, see Frustaci S, et al. 75
Gams R, see Arlin ZA, et al. 189

Ganapathi R, see Holleran WM, et al. 11
Geffen DB, see Klubes P, et al. 236
Gerin-Lajoie J, see Stewart DJ, et al. 91
Gilchrist NL, see Cummings J, et al. 80
Goddard PM, see Rutty CJ, et al. 251
Grattoni E, see Frustaci S, et al. 75
Gregory W, see Cullen M, et al. 157
Grigoletto E, see Frustaci S, et al. 75
Grönroos M, see Kangas L, et al. 109
Groth S, Nielsen H, Sørensen JB, Christensen AB, Pedersen AG, Rørth M: Acute and long-term nephrotoxicity of *cis*-platinum in man 191
Gunvén P, Theve NO, Peterson C: Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer 153

Harrap KR, see Rutty CJ, et al. 251
Harris AL, see Buamah PK, et al. 182
Hartley JA, Fox BW: Cross-linking between histones and DNA following treatment with a series of dimethane sulphonate esters 56
Henriques E, see Carmo-Pereira J, et al. 87
Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD: Pharmacokinetic study of fludarabine phosphate (NSC 312887) 277
Hill GJ, see Lea MA, et al. 231
Hill HZ, see Lea MA, et al. 231
Hirano M, see Ohno R, et al. 161
Hirota Y, see Ohno R, et al. 161
Holleran WM, DeGregorio MW, Ganapathi R, Wilbur JR, Macher BA: Characterization of cellular lipids in doxorubicin-sensitive and -resistant P388 mouse leukemia cells 11

Ikeda Y, see Ohno R, et al. 161
Imbert AM, see Bore P, et al. 171
Ishioka C, see Kanamaru R, et al. 43
Iven H, Brasch H: Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits 218
Iwamoto Y, Kuroiwa T, Aoki K, Baba T: "Two-route chemotherapy" using high-dose intraarterial neocarzinostatin and systemic tiopronin, its antidote, for rat limb tumor 247

Jackson DV Jr, McMahan RA, Pope EK, Case LD, Cooper MR, Kaplon MK, Richards F, II, Stuart JJ, White DR, Zekan PJ: Clinical trial of folinic acid to reduce vincristine neurotoxicity 281
Jacrot M, see Riondel J, et al. 137
James OFW, see Buamah PK, et al. 182
Jhanwar S, see Arlin ZA, et al. 189
Johansson R, see Kallio S, et al. 103
Jones MM, Basinger MA, Mitchell WM, Bradley CA: Inhibition of *cis*-diamminedichloroplatinum (II) – induced renal toxicity in the rat 38
Judson IR, see Rutty CJ, et al. 251

Kakuta H, see Kanamaru R, et al. 43
Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Pippo I, Sundquist H, Södervall M, Toivola R: A new triphenylethylene compound, Fc-1157 a. I. Hormonal effects 103
Kallio S, see Kangas L, et al. 109
Kanamaru R, Kakuta H, Sato T, Ishioka C, Wakui A: The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro 43
Kangas L, see Kallio S, et al. 103
Kangas L, Nieminen A-L, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R: A new triphenylethylene compound, Fc-1157 a. II Antitumor effects 109
Kaplinsky C, Yeger H, Estrov Z, Barankiewicz J, Pawlin G, Freedman MH, Cohen A: Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells 264
Kaplon MK, see Jackson DV Jr, et al. 281
Karjalainen A, see Kallio S, et al. 103
Karjalainen A, see Kangas L, et al. 109
Katsoulis C, see Alexopoulos CG, et al. 165
Kavanagh J, see Lu K, et al. 143
Kimura K, see Ohno R, et al. 161
Klubes P, Geffen DB, Cysyk RL: Comparison of the bioavailability of uridine in mice after either oral or parenteral administration 236
Kobayashi M, see Ohno R, et al. 161
Kokenberg E, Sonneveld P, Nooter K, van der Steuyt K, Löwenberg B: Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: A method analysis 63
Komar KA, see Seidenfeld J, et al. 16
Kroes ACM, Lindemans J, Schoester M, Abels J: Enhanced therapeutic effects of methotrexate in experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide 114
Kuhn JG, see Hersh MR, et al. 277
Kuroiwa T, see Iwamoto Y, et al. 247
Květina J, see Lázničková, et al. 133
Kvinnsland S, see Lønning PE, et al. 177

Laframboise G, see Stewart DJ, et al. 91
Landbeck G, see Erb N, et al. 53
Lázniček M, see Lázničková, et al. 133
Lázničková A, Lázniček M, Květina J, Drobnik J: Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats 133
Lea MA, Luke A, Velazquez O, Carpenter L, Martinson CF, Hill HZ, Hill GJ: Effects of sodium cyanate in mice bearing B16 melanoma 231
Lee FYF, Coe P, Workman P: Pharmacokinetic basis for the comparative antitumor activity and toxicity of chlorambucil, phenylacetic acid mustard and β,β-difluorochlorambucil (CB 7103) in mice 21
Lee FYF, Workman P: Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumor activity and acute toxicity of selected nitrogen mustards 30
Lena N, see Bore P, et al. 171
Leonard RCF, see Smyth JF, et al. 149
Lieber MM, see Appel PL, et al. 47
Lindemans J, see Kroes ACM, et al. 114
Lønning PE, Ueland PM, Kvinnsland S: The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of breast cancer 177
Loo TL, see Lu K, et al. 143
Löwenberg B, see Kokenberg E, et al. 63
Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, Loo TL: Clinical pharmacology of 4-demethoxydaunorubicin (DMDR) 143
Ludden TM, see Hersh MR, et al. 277
Luke A, see Lea MA, et al. 231

Macfarlane A, see Cullen M, et al. 157
Macfarlane J, see Cullen M, et al. 157
Macher BA, see Holleran WM, et al. 11
Macpherson JS, see Smyth JF, et al. 149
Maitland CG, see Taylor HG, et al. 292
Maroun JA, see Stewart DJ, et al. 91
Martinson CF, see Lea MA, et al. 231
McElnay JC, see Adair CG 95
McGivern D, see Cullen M, et al. 157
McGown AT, Fox BW: A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro 223
McMahan RA, see Jackson DV Jr, et al. 281
Meyer G, see Bore P, et al. 171
Mikhael NZ, see Nanji AA, et al. 274

Milas L, see Tofilon PJ, et al. 269
Millis R, see Mitchell I, et al. 289
Mitchell I, Deshpande N, Millis R, Rubens RD: The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease 289
Mitchell WM, see Jones MM, et al. 38
Mitomo Y, see Ohno R, et al. 161
Miwa Y, see Ohno R, et al. 161
Mizuno H, see Ohno R, et al. 161
Morgan D, see Cullen M, et al. 157
Mouriquand C, see Riondel J, et al. 137

Nanji AA, Stewart DJ, Mikhael NZ: Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity 274
Naujokas MF, see Seidenfeld J, et al. 16
Newell DR, see Rutty CJ, et al. 251
Ng A, see Brox LW, et al. 127
Nielsen H, see Groth S, et al. 191
Nieminen A-L, see Kangas L, et al. 109
Nooter K, see Kokenberg E, et al. 63

Oguri T, see Ohno R, et al. 161
Ohara K, see Ohno R, et al. 161
Ohno R, Hirano M, Yamagata K, Ohara K, Shirakawa S, Hirota Y, Kobayashi M, Yoshikawa S, Mitomo Y, Ikeda Y, Miwa Y, Oguri T, Mizuno H, Yamada H, Yamada K, Kimura K, The Tokai Blood Cancer Study Group: Treatment of leukemia and myelodysplastic syndromes with orally administered $N^4$-palmitoyl-l-β-D-arabinofuranosylcytosine 161
Oliveira Costa F, see Carmo-Pereira J, et al. 87

Pallikaris G, see Alexopoulos CG, et al. 165
Pawlin G, see Kaplinski C, et al. 264
Pedersen AG, see Groth S, et al. 191
Peest D, Bartels B, Dallmann I, Schedel I, Deicher H: Cytostatic drug sensitivity test for human multiple myeloma, measuring monoclonal immunoglobulin produced by bone marrow cells in vitro 69
Perilä M, see Kallio S, et al. 103
Perilä M, see Kangas L, et al. 109
Peterson C, see Gunvén P, et al. 153
Phillips JL, see Hersh MR, et al. 277
Picot F, see Riondel J, et al. 137
Pippo I, see Kallio S, et al. 103
Pollock E, see Brox LW, et al. 127
Pomeroy M, Fennelly JJ, Towers M: Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis 285
Pope EK, see Jackson DV Jr, et al. 281
Potier P, see Riondel J, et al. 137
Powis G, see Appel PL, et al. 47

Richards F, II, see Jackson DV Jr, et al. 281
Richards M, see Cullen M, et al. 157
Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P: Therapeutic response to taxol of six human tumors xenografted into nude mice 137
Robinson M, see Cullen M, et al. 157
Rørth M, see Groth S, et al. 191
Rubens RD, see Mitchell I, et al. 289
Rutty CJ, Judson IR, Abel G, Goddard PM, Newell DR, Harrap KR: Preclinical toxicology, pharmacokinetics and formulation of $N^2$, $N^4$, $N^6$-trihydroxymethyl-$N^2$, $N^4$, $N^6$-trimethylmelamine (Trimelamol), a water-soluble cytotoxic *s*-triazine which does not require metabolic activation 251

Sato T, see Kanamaru R, et al. 43
Savaraj N, see Lu K, et al. 143
Schedel I, see Peest D, et al. 69
Schoch I, see Arlin ZA, et al. 189
Schoester M, see Kroes ACM, et al. 114
Seidenfeld J, Komar KA, Naujokas MF, Block AL: Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs 16
Shirakawa S, see Ohno R, et al. 161
Shoemaker R, see Appel PL, et al. 47
Skillen AW, see Buamah PK, et al. 182
Smyth JF, Macpherson JS, Warrington PS, Leonard RCF, Wolf CR: The clinical pharmacology of mitozantrone 149
Södervall M, see Kallio S, et al. 103
Södervall M, see Kangas L, et al. 109
Sonneveld P, see Kokenberg E, et al. 63
Sørensen JB, see Groth S, et al. 191
Soukop M, see Cummings J, et al. 80
Soukop M, see Cunningham D, et al. 85
Soula G, see Akel G, et al. 121
Stableforth D, see Cullen M, et al. 157
Steiness E, see Wassermann K 241
Stewart DJ, Maroun JA, Cripps C, Young V, Laframboise G, Gerin-Lajoie J: Methotrexate and 5-fluorouracil in the treatment of squamous and other carcinomas of the head and neck 91
Stewart DJ, see Nanji AA, et al. 274
Stirland J, see Cullen M, et al. 157
Stuart JJ, see Jackson DV Jr, et al. 281
Sundquist H, see Kallio S, et al. 103

Taylor HG, Wolf CR, Maitland CG: Neurologic toxicity associated with hepatic artery infusion HAI of FUdR 292
The Midlands Small Cell Lung Cancer Group, see Cullen M, et al. 157
The Tokai Blood Cancer Study Group, see Ohno R, et al. 161
Theve NO, see Gunvén P, et al. 153
Tirelli U, see Frustaci S, et al. 75
Tofilon PJ, Vines CM, Milas L: N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity 269
Toivola R, see Kallio S, et al. 103
Toivola R, see Kangas L, et al. 109
Towers M, see Pomeroy M, et al. 285
Tumolo S, see Frustaci S, et al. 75

Ueland PM, see Lønning PE, et al. 177

Van der Steuyt K, see Kokenberg E, et al. 63
Velazquez O, see Lea MA, et al. 231
Veronesi A, see Frustaci S, et al. 75
Vines CM, see Tofilon PJ, et al. 269
Von Hoff DD, see Hersh MR, et al. 277

Wakui A, see Kanamaru R, et al. 43
Ward M, see Cullen M, et al. 157
Warrington PS, see Smyth JF, et al. 149
Wassermann K, Steiness E: Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites 241
White DR, see Jackson DV Jr, et al. 281
Wilbur JR, see Holleran WM, et al. 11
Wolf CR, see Smyth JF, et al. 149
Wolf CR, see Taylor HG, et al. 292
Woodroffe C, see Cullen M, et al. 157
Workman P, see Lee FYF, et al. 21
Workman P, see Lee FYF 30

Yamada H, see Ohno R, et al. 161
Yamada K, see Ohno R, et al. 161
Yamagata K, see Ohno R, et al. 161
Yeger H, see Kaplinsky C, et al. 264
Yoshikawa S, see Ohno R, et al. 161
Young V, see Stewart DJ, et al. 91

Zekan PJ, see Jackson DV Jr, et al. 281
Zijlstra WG, see de Graaf SSN, et al. 227

# Subject index of volume 17


Absorption 99
Acute leukemia 161
Adriamycin 80
AFP heterogeneity 182
Aminoglutethimide 177
m-AMSA 127
Anthracyclines 53
Antibiotics 218
Antibody targeting 197
Antiemetic trial 75
Antiestrogens 103, 109
Antineoplastic agents 109
Antitumor antibiotics 1

Binding sites 241
Bioavailability 99, 236
Blastic CML 189
Bleomycin 294
B16 melanoma 231
Body autoradiography 121
Breast cancer 87, 109, 177, 289
Breast carcinoma 289

Cellular lipids 11
Chemosensitivity 269
Chemosensitivity testing 259
Chemotherapy 157, 161, 182, 289
Chlorambucil 95, 99
Chlorambucil CB7103 21
*cis*-Diamminedichloroplatinum (II) 165
Cisplatin-induced nephrotoxicity 274
*cis*-Platinum 38
Chronic myelogenous leukemia 161
Cyanate 231
Cyclophosphamide 223
Cytostatic drug sensitivity test 69

Daunorubicin 63
Dexamethasone vs. metoclopramide 75
DMDR 143
DNA-crosslinking 16
DNA following treatment 56
Doxorubicin 11, 153, 241
Drug activity 47
Drug stability in vitro 1

Enzyme induction 177
Estrogen receptors 103

Fc-1157 a 103, 109
Fludarabine 277
5-Fu 43, 91

Gastrointestinal absorption 95
Gastrointestinal cancer 153
Glutathione 223

Head and neck cancer 91, 171
Hepatic artery infusion of FUdR 292
Hepatocellular carcinoma 182
Hepatocyte 47
High-dose methotrexate 227
Histones 56
HPLC 63
HPLC determination 53
Human lung tumor cells 259
Human tumor cell sensitivity 16
Human xenografts 137

Interaction 218

Kidney failure 185

Leukemia 63, 127
Lung cancer 85

MCF-7 109
Melphalan 95, 185
Metabolic activation 251
Methotrexate 91, 114, 218
Mice 121, 236
Misonidazole 121
Mitoxantrone 296
Mitozantrone 149, 189
Monoclonal immunoglobulin 69
MTT 259
MTX hydroxylation 171
MTX-VDS association 171
Multidrug resistance 259
Multiple myeloma 69, 185
Myeloblasts 127
Myelodysplastic syndromes 161

Nabilone vs. domperidone 285
Neocarzinostatin 247
Nephrotoxicity 209
Neuroblastoma cells 264
Neurotoxicity 281
Nitroimidazoles 30
$N^4$-Palmitoyl-1-β-D-arabinofurano-sylcytosine 161
Nephrotoxicity of *cis*-platinum 191
Nuclear receptor turnover 103
Nitrous oxide 114

Pharmacology 143
Pharmacokinetics 21, 30, 80, 133, 149, 218, 251, 277
Phosphoramide mustard 223
Platinum coordination complexes 209
P388 murine cells 11
Processing of preribosomal RNA 43
PLAC 161
Platinum cytostatics 133
Protein binding 133
Pulmonary fibrosis 294

Resistance 223
Rhabdomyosarcoma bearing rats 121
rRNA 43

Screening system 209
Small cell carcinoma 157
Squamous carcinoma 91
S-transferase 223

Tamoxifen 109
Taxol 137
TGU for small cell lung cancer 85
Thioinosine 264
Thymic mice 137
Tiopronin 247
Toremifene 103, 109
Toxicity 21, 30, 292
Trimelamol 251
Tubercidin toxicity 264
Tumor 121
Tween 80 effects 80
Two CMFP regimens 87
Two-route chemotherapy 247

Uridine 236
Uterotrophic effect 103

Vincristine 281
Vitamin B12 114

Warfarin 177